Strategies aimed at inhibiting or modulating WARS2-IT1 expression could improve the radiosensitivity of CRC cells by countering the resistance mechanisms orchestrated by CAF-derived factors, such as TGF-β1. The gene discussed is TGFB1; the disease is colorectal carcinoma.